CGRP and Hormones: Why Women Get More Migraines
Explore how CGRP migraine hormones estrogen interact to make migraines three times more common in women, and what to track to help your doctor.
Explore how CGRP migraine hormones estrogen interact to make migraines three times more common in women, and what to track to help your doctor.
The relationship between CGRP migraine hormones estrogen is one of the clearest explanations science has for a striking epidemiological fact: before puberty, boys and girls get migraines at roughly the same rate. After puberty, women experience them at nearly three times the rate of men. That gap tracks the reproductive years almost exactly and narrows again after menopause. Hormones are not the whole story, but they are a central chapter.
Calcitonin gene-related peptide (CGRP) is a small protein released by nerve fibers in and around the brain's blood vessels, particularly along the trigeminal nerve. When CGRP is released in significant amounts, it does two things that matter for migraine: it dilates blood vessels in the meninges (the membrane covering the brain) and it amplifies pain signals traveling from the head to the brainstem.
People who experience frequent migraines tend to have elevated CGRP levels during attacks, and some studies have measured elevated baseline levels between attacks as well. This is why understanding what CGRP is and how it works is a useful starting point before thinking about hormonal influences.
Estrogen does not act on CGRP in a simple on/off way. Instead, it shapes the entire sensitivity of the system.
Neurons in the trigeminal ganglia carry estrogen receptors. When estrogen is present at stable, moderate-to-high levels, it appears to keep CGRP expression somewhat in check and may reduce receptor sensitivity. When estrogen falls sharply, those brakes come off. CGRP release increases, trigeminal neurons become more excitable, and the threshold for a migraine drops.
This is why the most common migraine pattern tied to hormones is the perimenstrual migraine, arriving in the two days before menstruation or the first couple of days of bleeding. That window corresponds almost exactly with the steepest estrogen drop in the cycle. These attacks tend to be longer, harder to treat, and more likely to recur than migraines at other times of the month.
Estrogen is not static. It rises and falls across multiple timescales, and each shift creates a different risk profile.
The monthly cycle. Estrogen peaks around ovulation, then rises briefly again in the luteal phase before falling before menstruation. Many people find they are most vulnerable in the late luteal and early menstrual phases.
Perimenopause. In the years before menopause, estrogen does not simply decline in a straight line. It fluctuates erratically, sometimes spiking high before dropping low. This unpredictability can make migraines worse and harder to anticipate during this period. Some people who had well-controlled migraines find them resurging during perimenopause for exactly this reason.
Pregnancy. The second and third trimesters bring high, stable estrogen, and many people report a significant reduction in migraine frequency during this window. The first trimester is more variable. The postpartum period, when estrogen drops sharply, is a known high-risk window.
Postmenopause. After menstruation stops and estrogen settles at a consistently low level, many women find migraines improve. The improvement is not universal, and factors beyond estrogen (stress, sleep, other medical changes) play a role.
Progesterone is less studied than estrogen in the migraine context, but it is not irrelevant. Progesterone also influences CGRP activity and has its own effect on pain sensitivity. The ratio between estrogen and progesterone during the luteal phase may matter as much as either hormone in isolation. This complexity is part of why the hormonal picture is not fully mapped yet, and why your experience may not fit neatly into any single model.
Several conditions that affect hormone levels also tend to affect migraine frequency.
If any of these apply to you, it is worth raising with your neurologist and your gynecologist together. Hormonal migraine management sits at the intersection of both specialties, and the conversation goes better when both clinicians are informed.
A cycle diary alone is useful. A cycle diary combined with daily migraine data is much more useful. Specifically, tracking:
Even four to six weeks of consistent data can reveal patterns that neither you nor your doctor would spot from memory. Tools like the migraine reduction calculator can help you quantify whether a pattern is shifting over time. If you want a structured way to assess how migraines are affecting your daily life, the MIDAS calculator gives you a score you can bring to appointments.
For a deeper look at how to measure whether your management approach is working, tracking CGRP progress over time walks through what metrics actually matter.
Not all migraine patterns respond the same way to hormonal influences, partly because the underlying brain biology differs between people with episodic and chronic migraine. If you are averaging 15 or more migraine days per month, the hormonal component may be amplifying a pattern that already has other drivers. Your clinician will want to look at the full picture, including whether medication overuse is a factor.
Hormonal migraine is a recognized subtype, and neurologists who see a lot of migraine patients are familiar with it. What helps them is specificity. Instead of "I seem to get more migraines around my period," arriving with a log showing cycle day and migraine day for three months turns a vague impression into actionable data.
Questions worth raising: whether your current migraine pattern fits a hormonal profile, what your cycle looks like in the data, and what options exist for the perimenstrual window specifically. Your clinician is the only person who can advise on whether any hormonal or preventive approach is appropriate for your situation and medical history.
Migraine Tracker: CGRP Log is designed to make this kind of longitudinal tracking straightforward, so the data you bring to your appointment is clear and complete. Please consult your doctor or neurologist before making any changes to your current treatment plan.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
After puberty, women experience migraines at roughly three times the rate of men. The leading explanation is the interaction between estrogen levels and the migraine-signaling molecule CGRP. Estrogen fluctuations, particularly the drop before menstruation, appear to trigger CGRP release and sensitize pain pathways in the brain.
Learn how menopause and migraine hormones perimenopause are connected, what to expect as estrogen fluctuates, and how tracking helps your care team.
Explore the CGRP migraine aura connection: how this protein relates to visual symptoms, cortical spreading depression, and what to track.
Comparing CGRP monoclonal antibodies vs gepants? Learn how each class works, how they differ in use and timing, and what questions to bring to your clinician.